What is laser capture microdissection?

2026-09-22T09:13:07+01:0022 September 2026|

We take an inside look into what laser capture microdissection is and how it is enabling scientists at the Wellcome Sanger Institute to precisely isolate cells and reveal detailed insights into biology and disease.

One gene, many outcomes: Understanding variable cancer risk in PTEN hamartoma tumour syndrome

2026-08-24T09:30:48+01:0025 August 2026|

Changes in the PTEN gene, that causes PTEN hamartoma tumour syndrome (PHTS), can lead to a range of different manifestations that vary from person to person, including an increased risk of certain cancers. A new project aims to understand why some tissues in people with PHTS become cancerous, and if there is a way of identifying individuals with PTEN variants who are most at risk.

Detecting cancer early, together

2026-07-07T16:47:38+01:007 July 2026|

Dr Joe Christopher, clinician scientist in Dr Raheleh Rahbari’s team at the Wellcome Sanger Institute, is contributing to efforts to uncover cancer at its earliest stages – guided by patients, driven by curiosity and built on the belief that the biggest breakthroughs come from working together.

What are somatic mutations?

2026-01-15T11:52:25+00:0015 January 2026|

When most people think about genetic changes, or mutations, they imagine inherited conditions that are passed on from parents to offspring. However, the vast majority of mutations in our DNA are not inherited at all. Instead, they arise quietly, cell-by-cell throughout our lifetime. These are somatic mutations, and they are one of the most important – yet least understood – forces acting inside our bodies.

From somatic mutations to Quotient

2024-07-05T10:10:12+01:0021 November 2023|

We spoke to Dr IƱigo Martincorena, group leader at the Wellcome Sanger Institute and academic co-founder of Quotient Therapeutics. Quotient is a new company leveraging Sanger Institute research to innovate the way drugs are discovered.